Cytochrome P450 2C9 Genotyping Siponimod
Also known as: CYP2C9, Mayzent, Novartis, P450 CYP2C9, Siponimod
Use
CYP2C9 genotype testing is required to determine candidacy and the appropriate maintenance dosage for siponimod before treatment initiation. Siponimod is contraindicated in patients who have a CYP2C9*3/*3 genotype. Refer to the siponimod package insert for more details.
Special Instructions
Not provided.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Real-time polymerase chain reaction (RT-PCR)
Biomarkers
LOINC Codes
- 46724-1 - CYP2C9 allele Geno Bld/T
- 46724-1 - CYP2C9 allele Geno Bld/T
- 79716-7 - CYP2C9 gene prod met act imp Bld/T-Imp
- 69965-2 - Clinical cytogeneticist review
- 51969-4 - Gene analysis narr rpt Doc
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Unknown
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
Hemolysis; quantity not sufficient for analysis; improper container; single buccal swab; wet buccal swab
Other tests from different labs that may be relevant